Please login to the form below

Not currently logged in
Email:
Password:

Shire ADHD scholarship programme

Shire has partnered with a non-profit foundation to offer scholarships and coaching to support US students with attention-deficit/hyperactivity disorder during the transition from high school to college

Shire has partnered with a non-profit foundation to offer scholarships and coaching to support US students with attention-deficit/hyperactivity disorder (ADHD) during the transition from high school to college.

The Shire ADHD Scholarship Programme will award 25 graduating high school seniors who are going on to a higher education programme in sutumn 2011 with $2,000 in scholarship money each, as well as a year of ADHD coaching services provided by the Edge Foundation, a non-profit organisation that specialises in offering personal coaching to people of all ages who have ADHD.

The coaching programme will include weekly sessions with trained ADHD coaches who will help the students set goals and create action plans to meet those goals. The coaches will also offer support via phone and email between sessions.

"Students with ADHD struggle with the difficult transition from high school to higher education," according to the Edge Foundation. "Studies indicate that between 50 to 95 per cent of college students with ADHD drop out."

Winners will be selected based on application materials including a personal essay and a letter of recommendation. Applicants' work experience, volunteer/extracurricular activities, and academic transcripts will also be taken into account. Application materials are available on Shire's website and must be submitted by early July. The scholarships will be awarded in August.

The panel of judges includes two Shire executives as well as opinion-leaders such as a professor of psychiatry and paediatrics at the University of Pennsylvania School of Medicine; the president of the Attention Deficit Disorder Association; and the CEO of the advocacy group CHADD (Children and Adults with Attention Deficit/Hyperactivity Disorder.) The opinion-leaders are volunteering their time.

Shire's portfolio of ADHD drugs includes the once-daily therapy Intuniv (guanfacine), which was approved by the FDA in 2009 for ADHD and this year received a supplemental indication for use as adjunctive therapy to stimulants; the extended-release drug Vyvanse (lisdexamfetamine dimesylate), which was approved in the US in 2007; and Adderall XR (dextroamphetamine and amphetamine), which was approved in 2001.

26th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics